155 related articles for article (PubMed ID: 24971742)
1. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
Chu CH; Wang LY; Hsu KC; Chen CC; Cheng HH; Wang SM; Wu CM; Chen TJ; Li LT; Liu R; Hung CL; Yang JM; Kung HJ; Wang WC
J Med Chem; 2014 Jul; 57(14):5975-85. PubMed ID: 24971742
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
[TBL] [Abstract][Full Text] [Related]
3. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.
Hillringhaus L; Yue WW; Rose NR; Ng SS; Gileadi C; Loenarz C; Bello SH; Bray JE; Schofield CJ; Oppermann U
J Biol Chem; 2011 Dec; 286(48):41616-41625. PubMed ID: 21914792
[TBL] [Abstract][Full Text] [Related]
4. In-silico guided chemical exploration of KDM4A fragments hits.
Lombino J; Vallone R; Cimino M; Gulotta MR; De Simone G; Morando MA; Sabbatella R; Di Martino S; Fogazza M; Sarno F; Coronnello C; De Rosa M; Cipollina C; Altucci L; Perricone U; Alfano C
Clin Epigenetics; 2023 Dec; 15(1):197. PubMed ID: 38129913
[TBL] [Abstract][Full Text] [Related]
5. Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor.
Giordano A; Del Gaudio F; Johansson C; Riccio R; Oppermann U; Di Micco S
ChemMedChem; 2018 Jun; 13(12):1160-1164. PubMed ID: 29633584
[TBL] [Abstract][Full Text] [Related]
6. KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis.
Kupershmit I; Khoury-Haddad H; Awwad SW; Guttmann-Raviv N; Ayoub N
Nucleic Acids Res; 2014 Jun; 42(10):6168-82. PubMed ID: 24728997
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis.
Pichavaram P; Jablonowski CM; Fang J; Fleming AM; Gil HJ; Boghossian AS; Rees MG; Ronan MM; Roth JA; Morton CL; Zambetti GP; Davidoff AM; Yang J; Murphy AJ
Mol Cancer Ther; 2024 Apr; 23(4):478-491. PubMed ID: 37988559
[TBL] [Abstract][Full Text] [Related]
8. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
Chin YW; Han SY
Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
[TBL] [Abstract][Full Text] [Related]
9. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
Duan L; Rai G; Roggero C; Zhang QJ; Wei Q; Ma SH; Zhou Y; Santoyo J; Martinez ED; Xiao G; Raj GV; Jadhav A; Simeonov A; Maloney DJ; Rizo J; Hsieh JT; Liu ZP
Chem Biol; 2015 Sep; 22(9):1185-96. PubMed ID: 26364928
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Ye Q; Holowatyj A; Wu J; Liu H; Zhang L; Suzuki T; Yang ZQ
Am J Cancer Res; 2015; 5(4):1519-30. PubMed ID: 26101715
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of lysine demethylases in DNA damage response: dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites.
Khoury-Haddad H; Nadar-Ponniah PT; Awwad S; Ayoub N
Cell Cycle; 2015; 14(7):950-8. PubMed ID: 25714495
[TBL] [Abstract][Full Text] [Related]
12. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W
Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of demethylases by GSK-J1/J4.
Heinemann B; Nielsen JM; Hudlebusch HR; Lees MJ; Larsen DV; Boesen T; Labelle M; Gerlach LO; Birk P; Helin K
Nature; 2014 Oct; 514(7520):E1-2. PubMed ID: 25279926
[No Abstract] [Full Text] [Related]
14. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
15. Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.
Leurs U; Lohse B; Rand KD; Ming S; Riise ES; Cole PA; Kristensen JL; Clausen RP
ACS Chem Biol; 2014 Sep; 9(9):2131-8. PubMed ID: 25014588
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway.
Awwad SW; Ayoub N
Biol Open; 2015 Mar; 4(4):498-504. PubMed ID: 25770186
[TBL] [Abstract][Full Text] [Related]
17. Advances in the development of histone lysine demethylase inhibitors.
Maes T; Carceller E; Salas J; Ortega A; Buesa C
Curr Opin Pharmacol; 2015 Aug; 23():52-60. PubMed ID: 26057211
[TBL] [Abstract][Full Text] [Related]
18. The role of the histone demethylase KDM4A in cancer.
Guerra-Calderas L; González-Barrios R; Herrera LA; Cantú de León D; Soto-Reyes E
Cancer Genet; 2015 May; 208(5):215-24. PubMed ID: 25633974
[TBL] [Abstract][Full Text] [Related]
19. Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates.
Williams ST; Walport LJ; Hopkinson RJ; Madden SK; Chowdhury R; Schofield CJ; Kawamura A
Epigenetics; 2014 Dec; 9(12):1596-603. PubMed ID: 25625844
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Li X; Dong S
Med Oncol; 2015 Mar; 32(3):53. PubMed ID: 25636512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
